Media & Press

FOR IMMEDIATE RELEASE [Covington, KY---September 17, 2021] Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced today that Gilles Tapolsky PhD, MBA, Bexion’s Vice President, Pharmacology will be virtually presenting preclinical and clinical data of the Company’s lead compound, BXQ-350.  The presentation will be made at the Discovery on Target (DOT) Conference in the Immunology and ... Read More

FOR IMMEDIATE RELEASE [Covington, KY---April 20, 2021] Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced today that an abstract submitted for an eTalk Session at the CIMT annual meeting to be held virtually May 10-12, 2021 has been chosen for presentation. Every year, the CIMT Annual Meeting connects the global cancer immunotherapy community in the ... Read More

Jupiter, FL— The award-winning series, Advancements with Ted Danson, will focus on an innovative, targeted approach to treating a range of diseases during 3Q/2021. Check local listings for more information. The diseases for which medicine offers few effective options – advanced cancer (or even early-stage cancer for certain types), neurodegenerative diseases and autoimmune diseases – persist because ... Read More

FOR IMMEDIATE RELEASE Covington, KY February 22, 2021 Bexion Pharmaceuticals, Inc. announced today that it has added Olivia F. Kirtley to its Board of Directors. Ms. Kirtley, a Certified Public Accountant and Chartered Global Management Accountant, is a business consultant on strategic, risk and corporate governance issues. She brings to Bexion extensive experience as ... Read More

FOR IMMEDIATE RELEASE Covington, KY, December 10, 2020               Bexion Pharmaceuticals, Inc., a clinical stage biotech company focused on the discovery and development of life-changing treatments by leveraging the lysosome's roles in solid tumors and cell death with an initial focus on cancer, announced today the database lock for the Phase 1 study of BXQ-350 in adult patients ... Read More

FOR IMMEDIATE RELEASE Covington, KY November 16, 2020               Bexion Pharmaceuticals, Inc. announced today that it has added RJ. Tesi, M.D. to its Board of Directors. Dr. Tesi has a distinguished career as a biotech entrepreneur and an experienced surgeon. Currently, he is President, Chief Executive Officer and acting Chief Medical Officer of INmune Bio (NASDAQ: ... Read More

FOR IMMEDIATE RELEASE [Covington, KY] September 30, 2020 Bexion Pharmaceuticals, Inc., a clinical stage biotechnology company focused on developing innovative cures for cancer, announced that the Federal Drug Administration (FDA) has granted the company’s request for rare pediatric disease designation for BXQ-350, Bexion’s lead therapeutic, for the treatment of diffuse intrinsic pontine glioma (DIPG) and ... Read More

FOR IMMEDIATE RELEASE [Covington, KY: September 16, 2020] Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative cures for cancer announced today it will present clinical and pre-clinical electronic posters with audio presentations at the Society of Neuro-Oncology (SNO) annual virtual conference to be held November 19-21, 2020. "We ... Read More

For Immediate Release, Covington, KY May 13, 2020 Bexion Pharmaceuticals announced today that the following three abstracts submitted to the 2020 American Society of Clinical Oncology (ASCO) have been accepted for oral or poster presentation: Oral Presentation Tolerability and preliminary efficacy of BXQ-350 for refractory solid tumors and high-grade gliomas: First-in-human, first-in-class phase I trial. ... Read More

FOR IMMEDIATE RELEASE [Covington, KY May 6, 2020] Bexion Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted the company Orphan Drug Designation for its proprietary drug, BXQ-350, for the treatment of malignant glioma, including diffuse intrinsic pontine glioma (DIPG). DIPG primarily affects children, with most diagnoses occurring between 5 ... Read More